Your browser doesn't support javascript.
loading
A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma.
Ligon, John A; Sundby, R Taylor; Wedekind, Mary F; Arnaldez, Fernanda I; Del Rivero, Jaydira; Wiener, Lori; Srinivasan, Ramaprasad; Spencer, Melissa; Carbonell, Amanda; Lei, Haiyan; Shern, John; Steinberg, Seth M; Figg, William D; Peer, Cody J; Zimmerman, Sara; Moraly, Josquin; Xu, Xia; Fox, Stephen; Chan, King; Barbato, Michael I; Andresson, Thorkell; Taylor, Naomi; Pacak, Karel; Killian, J Keith; Dombi, Eva; Linehan, W Marston; Miettinen, Markku; Piekarz, Richard; Helman, Lee J; Meltzer, Paul; Widemann, Brigitte; Glod, John.
Afiliación
  • Ligon JA; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Sundby RT; Department of Pediatrics, Division of Hematology/Oncology, University of Florida, Gainesville, Florida.
  • Wedekind MF; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Arnaldez FI; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Del Rivero J; AstraZeneca, Cambridge, United Kingdom.
  • Wiener L; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Srinivasan R; Developmental Therapeutics Branch, CCR, NCI, Bethesda, Maryland.
  • Spencer M; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Carbonell A; Urologic Oncology Branch, CCR, NCI, Baltimore, Maryland.
  • Lei H; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Shern J; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Steinberg SM; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Figg WD; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Peer CJ; Biostatistics and Data Management Section, CCR, NCI, Bethesda, Maryland.
  • Zimmerman S; Clinical Pharmacology Program, NCI/NIH, Bethesda, Maryland.
  • Moraly J; Clinical Pharmacology Program, NCI/NIH, Bethesda, Maryland.
  • Xu X; Clinical Pharmacology Program, NCI/NIH, Bethesda, Maryland.
  • Fox S; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Chan K; Laboratory of physiopathology and treatment of Hematological malignancies, Institut imagine, INSERM U1153, Université de Paris, Paris, France.
  • Barbato MI; Cancer Research Technology Program, Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
  • Andresson T; Cancer Research Technology Program, Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
  • Taylor N; Cancer Research Technology Program, Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
  • Pacak K; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.
  • Killian JK; Cancer Research Technology Program, Protein Characterization Laboratory, Frederick National Laboratory for Cancer Research, Leidos Biomedical Research, Inc., Frederick, Maryland.
  • Dombi E; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Linehan WM; Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, Maryland.
  • Miettinen M; Foundation Medicine, Inc., Cambridge, Massachusetts.
  • Piekarz R; Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Helman LJ; Urologic Oncology Branch, CCR, NCI, Baltimore, Maryland.
  • Meltzer P; Laboratory Pathology, CCR, NCI, Bethesda, Maryland.
  • Widemann B; Cancer Therapy Evaluation Program, Division of Cancer Treatments and Diagnosis, NCI, Bethesda, Maryland.
  • Glod J; Osteosarcoma Institute, Dallas, Texas.
Clin Cancer Res ; 29(2): 341-348, 2023 01 17.
Article en En | MEDLINE | ID: mdl-36302175
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Paraganglioma / Feocromocitoma / Productos Biológicos / Carcinoma de Células Renales / Neoplasias de las Glándulas Suprarrenales / Tumores del Estroma Gastrointestinal / Neoplasias Renales Tipo de estudio: Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Paraganglioma / Feocromocitoma / Productos Biológicos / Carcinoma de Células Renales / Neoplasias de las Glándulas Suprarrenales / Tumores del Estroma Gastrointestinal / Neoplasias Renales Tipo de estudio: Risk_factors_studies Límite: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article